Clinical Study
Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment
Table 1
Serum concentrations of measured parameters in healthy controls and patients with multiple myeloma.
| | | Mean ± SD | (Mann Whitney) |
| OPG pmol/L | | | | Control | 20 | | < 0.03 | Patients | 54 | | | RANKL pmol/L | | | | Control | 20 | | = 0.007 | Patients | 54 | | | RANKL/OPG | | | | Control | 20 | | NS | Patients | 54 | | | HGF pg/mL | | | | Control | 20 | | < 0.001 | Patients | 54 | | | LDH IU/L | | | | Control | 20 | | < 0.01 | Patients | 54 | | | VEGF pg/mL | | | | Control | 20 | | < 0.001 | Patients | 54 | | | B2M mg/dL | | | | Control | 20 | | < 0.001 | Patients | 54 | | | CRP mg/L | | | | Control | 20 | | < 0.001 | Patients | 54 | | | IL-6 pg/mL | | | | Control | 20 | | < 0.001 | Patients | 54 | | |
|
|